Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04839666
Other study ID # 2021-
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2010
Est. completion date August 31, 2016

Study information

Verified date May 2023
Source Universitair Ziekenhuis Brussel
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators would only include the children who received propofol (Propolipid, Fresenius Kabi, Schelle, Belgium) for sedation, the investigators would exclude the children that didn't receive propofol during the procedure. The investigators would analyze the incidence of hypersensitivity reaction to propofol in children allergic to egg, soy or both egg and soy and to compare those with the incidence of hypersensitivity reactions in children without allergy to egg and/or to soy. Those data were retrieved following longitudinal follow-up after the intervention. Allergy tests by skin and radioallergosorbent tests were performed in all children before the gastrointestinal endoscopy under anesthesia took place, but no results were known at the time of the sedation. A patient was defined as allergic to egg and/or soy if the patient had specific S-IgE level more than the normal level set by our institution (0.35 kU/L). The investigators would also investigate the influence of other obtained parameters in the dataset (age, ASA score, weight category, type of investigation, respiratory and neurological comorbidities, respiratory infections, GERD, other allergies) on those results with multivariate analysis. We considered that clinical features suggesting a hypersensitivity reaction present during anaesthesia were cutaneous, respiratory or cardiovascular manifestations. Depending on the severity of the reaction, necessitating prompt hemodynamic resuscitation with the administration of epinephrine, antihistamines, inhaled beta-agonists or corticosteroids.


Recruitment information / eligibility

Status Completed
Enrollment 2299
Est. completion date August 31, 2016
Est. primary completion date August 31, 2016
Accepts healthy volunteers No
Gender All
Age group N/A to 16 Years
Eligibility Inclusion Criteria: - diagnostic gastrointestinal endoscopy - monitored anesthesia - received propofol during the procedure - allergic to egg and/or soy if the patient had specific S-IgE level more than the normal level set by our institution (0.35 kU/L) Exclusion Criteria: - Procedure without administration of propofol

Study Design


Intervention

Drug:
Propofol
Perioperatively propofol administration

Locations

Country Name City State
Belgium UZ Brussel Jette Brussel

Sponsors (1)

Lead Sponsor Collaborator
Universitair Ziekenhuis Brussel

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with a hypersensitivity reaction clinical features suggesting a hypersensitivity reaction present during anaesthesia were cutaneous, respiratory or cardiovascular manifestations. minutes, during surgery
Secondary Influence of gender on hypersensitivity reaction See if there is a link or influence of gender on hypersensitivity reaction minutes, during surgery
Secondary Influence of ASA on hypersensitivity reaction See if there is a link or influence of ASA on hypersensitivity reaction minutes, during surgery
Secondary Influence of type of procedure on hypersensitivity reaction See if there is a link or influence of type of procedure on hypersensitivity reaction minutes, during surgery
Secondary Influence of age on hypersensitivity reaction See if there is a link or influence of age on hypersensitivity reaction minutes, during surgery
Secondary Influence of weight on hypersensitivity reaction See if there is a link or influence of weight on hypersensitivity reaction minutes, during surgery
Secondary Influence of height on hypersensitivity reaction See if there is a link or influence of height on hypersensitivity reaction minutes, during surgery
Secondary Influence of the experience of the gastroenterologist on hypersensitivity reaction See if there is a link or influence of experience of gastroenterologist on hypersensitivity reaction minutes, during surgery
Secondary Influence of a respiratory comorbitidity on hypersensitivity reaction See if there is a link or influence of respiratory comorbidity on hypersensitivity reaction. minutes, during surgery
Secondary Influence of a neurological comorbidity on hypersensitivity reaction See if there is a link or influence of a neurological comorbidity on hypersensitivity reaction minutes, during surgery
Secondary Influence of reason for investigation on hypersensitivity reaction See if there is a link or influence of the reason for investigation on hypersensitivity reaction minutes, during surgery
Secondary Influence of a respiratory infection on hypersensitivity reaction See if there is a link or influence of a respiratory infection on hypersensitivity reaction. minutes, during surgery
Secondary Influence of GERD on hypersensitivity reaction See if there is a link or influence of GERD on hypersensitivity reaction minutes, during surgery
Secondary Influence of an allergy besides egg or soy on hypersensitivity reaction See if there is a link or influence of another allergy besides egg or soy on hypersensitivity reaction. minutes, during surgery
Secondary Influence of ketamine on hypersensitivity reaction See if there is a link or influence of ketamine on hypersensitivity reaction. minutes, during surgery
Secondary Influence of midazolam on hypersensitivity reaction See if there is a link or influence of midazolam on hypersensitivity. minutes, during surgery
See also
  Status Clinical Trial Phase
Completed NCT04531540 - Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test) Phase 3
Completed NCT00988065 - Sugammadex Hypersensitivity Study (Study P06042) Phase 1
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Completed NCT02588326 - Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays Phase 1
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT02360072 - Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
Completed NCT02352168 - Airway Inflammation in Children With Allergic Rhinitis and Intervention N/A
Completed NCT01904604 - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Phase 2
Completed NCT01494649 - Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity N/A
Enrolling by invitation NCT05039229 - Measures for Bioaerosol Reduction in the Salmon Industry N/A
Enrolling by invitation NCT05675241 - Characterizing the Inflammation Around Dental Implants
Completed NCT04006106 - Defining ENDOtypes in Perioperative Hypersensitivity by Extensive Cellular and Molecular PHENotyping (ENDOPHEN)
Completed NCT04605471 - A Study to Learn More About the Safety of Ultravist in Children and in the Elderly
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Terminated NCT05247567 - Quaternary Ammonium and Immunization in Hairdressers N/A
Completed NCT05119751 - Vestibular Versus Sublingual Route of AIT Tablets Phase 4
Recruiting NCT06065137 - Standardised Drug Provocation Testing in Perioperative Hypersensitivity N/A
Active, not recruiting NCT05960266 - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study Early Phase 1
Not yet recruiting NCT04485299 - Clinical Assessment of Bifluorid 10 vs Varnish Fluoride on The Exposed Hypersensitive Cervical Dentin in Adult Patient Phase 2/Phase 3
Completed NCT02686827 - DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients. Phase 2